Q-omics provides the consensus-scored ZDHHC14 profile across patient tissues and cancer cell-line models. ZDHHC14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZDHHC14 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZDHHC14 RNA expression shows 16,736 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, KIRC, and KIRP as cancer lineages where ZDHHC14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC14 survival associations across molecular data types. ZDHHC14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC14 RNA expression–survival associations across cancer types. High ZDHHC14 expression shows unfavorable associations in MESO, LGG and UCEC, but favorable associations in SKCM, KIRC and PAAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZDHHC14 RNA expression.
This table summarizes ZDHHC14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC14 shows lower tumor expression in KIRC, THCA, KICH, LUAD and UCEC and higher tumor expression in HNSC. The KIRC box plot shows higher ZDHHC14 RNA expression in normal versus tumor tissue (log2 FC = −0.902, t-test p < 0.001).
This table shows molecular features associated with ZDHHC14 in patient tissues and cancer cell lines. In patient samples, ZDHHC14 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SKIN.
